Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for…
Read More
Enveric is advancing EB-373, a psilocin prodrug for anxiety disorders and its EVM301 Series of novel non-hallucinatory brain plastogens to treat mental health disorders. CAMBRIDGE, Mass. - Enveric Biosciences, Inc.…
Read More
CEO Joseph Tucker, Ph.D., to discuss Enveric's pipeline and therapeutic opportunities in fireside chat and "NextGen Psychedelics" panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),…
Read More
Key Highlights Nominated EB-373 as lead development candidate for the treatment of anxiety disorders EB-373 is a next generation proprietary psilocin prodrug selected from Enveric's EVM201 Series and developed leveraging…
Read More
EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
First-in-human clinical trial investigating Enveric's lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or…
Read More
Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated…
Read More
30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
